Paul Liknaitzky is Head of Clinical Psychedelic Research at Monash University, and Chief Principal Investigator on a program of psychedelic trials at Monash University. He is a joint Research Fellow within the Turner Institute (School of Psychological Sciences) and the Dept of Psychiatry (School of Clinical Sciences) at Monash University. Paul has an Honours in Neuroscience and a PhD in Psychology from the University of Melbourne, and has Adjunct or Honorary appointments at St Vincent’s Hospital, Macquarie University, Deakin University, and the University of Melbourne. He is an Investigator on a number of Australia’s first few ethically-approved psychedelic trials, coordinates Australia’s first applied psychedelic therapist training programs, has obtained the first industry funding and partnership for psychedelics in Australia, is establishing Australia’s largest psychedelic trial, and leads Australia’s first clinical psychedelic lab. His work is focused on developing a rigorous program of research in psychedelic medicine that seeks to evaluate therapeutic effects, innovate on treatment design, mitigate known risks, explore potential drawbacks, and understand therapeutic mechanisms.